Eli Lilly & Co.’s novel performance-based contract with Harvard Pilgrim Health Care for Trulicity (dulaglutide) ties price rebates to how well the GLP-1 agonist performs in reducing A1C blood sugar levels versus other drugs in its class.
Trulicity will be compared to Novo Nordisk AS’s Victoza (liraglutide), AstraZeneca PLC’s Byetta (exenatide) and Bydureon (long-acting exenatide),...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?